These results suggest that uterine and ovarian carcinosarcomas, which are notoriously resistant to multiple clinically available chemotherapeutic agents [5,6], can be made highly sensitive to immune-mediated cytotoxicity when effector cells are engaged by the Trop-2-specific antibody, hRS7. Here, TACSTD2 is linked to ovarian carcinosarcoma.